BMJ on herbals
This article was originally published in The Tan Sheet
Executive Summary
Editorial appearing in the July 9 British Medical Journal challenges natural products' reliance on "folklore" to support medicinal claims. The article refers to the EU Herbal Medicinal Products Directive, which will be implemented by October and requires herbal products to have a demonstrated 30-year history of safe use prior to sale. The editorial also states "without the evidence of efficacy, it is hard to judge the safety of herbal medicines, not least because the risk of an adverse effect that might be acceptable for an effective treatment will be unacceptable for an ineffective one." The UK Medicines & Healthcare products Regulatory Agency said the editorial "fairly" points out that strength of evidence of herbal products' efficacy "varies widely." However, MHRA maintained the "higher standards introduced by the new regulatory regime represent an important advance for the consumer"...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.